ZURICH, October 2, 2015 /PRNewswire/ --
Kuros Biosurgery AG, a biotechnology company developing novel biomaterials and bioactive-biomaterial combination products, today announces that it has been chosen to make two podium presentations on its novel orthobiologics at the upcoming 2015 Orthopedic Trauma Association Annual Meeting, 7-10 October in San Diego, California.
On Friday 9 October at 8.31am, Dr. Tom Lyon, Director of Orthopedics and Chief of Orthopedic Trauma at NYU Lutheran Medical Center will present results of a Phase IIb clinical trial comparing the efficacy and safety of Kuros' novel PTH based bone graft substitute (KUR-111) to autograft in patients with tibial plateau fractures (TPF).
On Wednesday 7 October at 11.01am. Dr. Jason Schense, Chief Technology Officer of Kuros will present the results of a large ovine tibial plateau defects study on the efficacy of the novel bone graft substitute (KUR-111) based on the local retention of TGplPTH1-34 in a fibrin matrix.
Kuros is focused on the development of novel biomaterials and bioactive-biomaterial combination products in therapeutic areas covering sealants and orthobiologics.
Kuros has a late stage pipeline which has generated highly encouraging data in multiple clinical studies. Its most advanced sealant product candidate is KUR-023, a sealant that has successfully completed European clinical development and is close to being CE Marked. KUR-111 and KUR-113, Kuros' most advanced orthobiologic products have both met the primary endpoints in large well controlled Phase II clinical studies and are progressing towards Phase III.
Kuros has two biomaterial technology platforms, one based on fibrin sealants and the other based on its own proprietary synthetic technology that can mimic fibrin in many of its attributes. These materials can be used alone or in combination with biologically active molecules, and can be delivered in many forms including as injectable liquids, sprays, gels, pastes or preformed implants. The incorporation of the biologically active molecules into the matrices aims to maximize their activity by retention at the site of action. Kuros has a number of methodologies to achieve the desired retention and release profiles of the biologically active molecules. The products are designed to combine ease of application with localized delivery.
The company is located in Zurich, Switzerland.
For more information, visit: http://www.kuros.ch
Didier Cowling, CEO
Alistair Irvine, CBO
For Media Enquires:
Citigate Dewe Rogerson
David Dible, Sylvie Berrebi